CRITICAL REVIEW OF AVAILABLE TREATMENT OPTIONS FOR TREATMENT REFRACTORY DEPRESSION AND ANXIETY - CLINICAL AND ETHICAL DILEMMAS

Treatment-resistant mood and anxiety disorders require an intensive therapeutic approach, and it should balance benefits and adverse effects or other potential detrimental effects of medications. The goal of treatment is to provide consistent and lasting improvement in symptoms of depression and anx...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicinski pregled 2016-10, Vol.69 (5-6), p.171-176
Hauptverfasser: Kolar, Dusan, Kolar, Michael V
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 176
container_issue 5-6
container_start_page 171
container_title Medicinski pregled
container_volume 69
creator Kolar, Dusan
Kolar, Michael V
description Treatment-resistant mood and anxiety disorders require an intensive therapeutic approach, and it should balance benefits and adverse effects or other potential detrimental effects of medications. The goal of treatment is to provide consistent and lasting improvement in symptoms of depression and anxiety. Beozodiazepines are effective for anxiety symptoms, but with no sustained treatment effects. Other medication treatment options for anxiety disorders are outlined. Ketamine is usually very effective in treating maior depressive disorder but without sustained benefits. Loog-term use may pose a signiticant risk of developing tolerance and dependence. Stimulant medication augmentation for treatment-resistant depression is effective for residual symptoms of depression, but effects are usually short-lasting and it sounds mor as an artificial way of improving energy, alertness and cognitive functioning. Synthetic cannabinoids and medical marijuana are increasingly prescribed for various medical conditions. but more recently also for patients with mood and anxiety disorders. All of these treatments may raise ethical dilemmas about appropriateness of prescribing these medications and a number of questions regarding the optimal treatment for patients with treatment-resistant depression and treatment refractory anxiety disorders.
doi_str_mv 10.2298/mpns1606171k
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2030936061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2030936061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c244k-c56026bbafada7297c6276a33e890a93cb1456d3c3918d09a356a80170e7633f3</originalsourceid><addsrcrecordid>eNpNkDtPwzAURi0EoqWwMSOPDAT8aBx7DKlDI9KkSkyhU-Q8KpU2bYnpwMJvJ32AGK7u1aej70oHgGuM7gkR_KHerAxmiGEHL05AF3OCLIdyegq6CBHb4hjZHXBhzDtqIYb4OegQwQTlfbsLvr0kUIHnhjCRk0C-wtiH7sQNQvcxlFAl0lUjGSkYj1UQRyn04-Rfmkg_cT0VJ1M4kONEpmkLQTcatPMWSDWFFvTCINo_2MVSDff3IAjlaOSml-BsppemujruHnjxpfKGVhg_7UCrIP3-wipshgjLcz3TpXaIcApGHKYprbhAWtAix32blbSgAvMSCU1tpjnCDqocRumM9sDtoXfTrD-2lfnM6rkpquVSr6r11mQEUSTozmKL3h3Qolkb01SzbNPMa918ZRhlO-PZaBylR-PPLX5zbN7mdVX-wb-K6Q_uH3C8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2030936061</pqid></control><display><type>article</type><title>CRITICAL REVIEW OF AVAILABLE TREATMENT OPTIONS FOR TREATMENT REFRACTORY DEPRESSION AND ANXIETY - CLINICAL AND ETHICAL DILEMMAS</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kolar, Dusan ; Kolar, Michael V</creator><creatorcontrib>Kolar, Dusan ; Kolar, Michael V</creatorcontrib><description>Treatment-resistant mood and anxiety disorders require an intensive therapeutic approach, and it should balance benefits and adverse effects or other potential detrimental effects of medications. The goal of treatment is to provide consistent and lasting improvement in symptoms of depression and anxiety. Beozodiazepines are effective for anxiety symptoms, but with no sustained treatment effects. Other medication treatment options for anxiety disorders are outlined. Ketamine is usually very effective in treating maior depressive disorder but without sustained benefits. Loog-term use may pose a signiticant risk of developing tolerance and dependence. Stimulant medication augmentation for treatment-resistant depression is effective for residual symptoms of depression, but effects are usually short-lasting and it sounds mor as an artificial way of improving energy, alertness and cognitive functioning. Synthetic cannabinoids and medical marijuana are increasingly prescribed for various medical conditions. but more recently also for patients with mood and anxiety disorders. All of these treatments may raise ethical dilemmas about appropriateness of prescribing these medications and a number of questions regarding the optimal treatment for patients with treatment-resistant depression and treatment refractory anxiety disorders.</description><identifier>ISSN: 0025-8105</identifier><identifier>EISSN: 1820-7383</identifier><identifier>DOI: 10.2298/mpns1606171k</identifier><identifier>PMID: 29693845</identifier><language>eng</language><publisher>Serbia</publisher><ispartof>Medicinski pregled, 2016-10, Vol.69 (5-6), p.171-176</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c244k-c56026bbafada7297c6276a33e890a93cb1456d3c3918d09a356a80170e7633f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29693845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kolar, Dusan</creatorcontrib><creatorcontrib>Kolar, Michael V</creatorcontrib><title>CRITICAL REVIEW OF AVAILABLE TREATMENT OPTIONS FOR TREATMENT REFRACTORY DEPRESSION AND ANXIETY - CLINICAL AND ETHICAL DILEMMAS</title><title>Medicinski pregled</title><addtitle>Med Pregl</addtitle><description>Treatment-resistant mood and anxiety disorders require an intensive therapeutic approach, and it should balance benefits and adverse effects or other potential detrimental effects of medications. The goal of treatment is to provide consistent and lasting improvement in symptoms of depression and anxiety. Beozodiazepines are effective for anxiety symptoms, but with no sustained treatment effects. Other medication treatment options for anxiety disorders are outlined. Ketamine is usually very effective in treating maior depressive disorder but without sustained benefits. Loog-term use may pose a signiticant risk of developing tolerance and dependence. Stimulant medication augmentation for treatment-resistant depression is effective for residual symptoms of depression, but effects are usually short-lasting and it sounds mor as an artificial way of improving energy, alertness and cognitive functioning. Synthetic cannabinoids and medical marijuana are increasingly prescribed for various medical conditions. but more recently also for patients with mood and anxiety disorders. All of these treatments may raise ethical dilemmas about appropriateness of prescribing these medications and a number of questions regarding the optimal treatment for patients with treatment-resistant depression and treatment refractory anxiety disorders.</description><issn>0025-8105</issn><issn>1820-7383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpNkDtPwzAURi0EoqWwMSOPDAT8aBx7DKlDI9KkSkyhU-Q8KpU2bYnpwMJvJ32AGK7u1aej70oHgGuM7gkR_KHerAxmiGEHL05AF3OCLIdyegq6CBHb4hjZHXBhzDtqIYb4OegQwQTlfbsLvr0kUIHnhjCRk0C-wtiH7sQNQvcxlFAl0lUjGSkYj1UQRyn04-Rfmkg_cT0VJ1M4kONEpmkLQTcatPMWSDWFFvTCINo_2MVSDff3IAjlaOSml-BsppemujruHnjxpfKGVhg_7UCrIP3-wipshgjLcz3TpXaIcApGHKYprbhAWtAix32blbSgAvMSCU1tpjnCDqocRumM9sDtoXfTrD-2lfnM6rkpquVSr6r11mQEUSTozmKL3h3Qolkb01SzbNPMa918ZRhlO-PZaBylR-PPLX5zbN7mdVX-wb-K6Q_uH3C8</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Kolar, Dusan</creator><creator>Kolar, Michael V</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20161001</creationdate><title>CRITICAL REVIEW OF AVAILABLE TREATMENT OPTIONS FOR TREATMENT REFRACTORY DEPRESSION AND ANXIETY - CLINICAL AND ETHICAL DILEMMAS</title><author>Kolar, Dusan ; Kolar, Michael V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c244k-c56026bbafada7297c6276a33e890a93cb1456d3c3918d09a356a80170e7633f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kolar, Dusan</creatorcontrib><creatorcontrib>Kolar, Michael V</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medicinski pregled</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kolar, Dusan</au><au>Kolar, Michael V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CRITICAL REVIEW OF AVAILABLE TREATMENT OPTIONS FOR TREATMENT REFRACTORY DEPRESSION AND ANXIETY - CLINICAL AND ETHICAL DILEMMAS</atitle><jtitle>Medicinski pregled</jtitle><addtitle>Med Pregl</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>69</volume><issue>5-6</issue><spage>171</spage><epage>176</epage><pages>171-176</pages><issn>0025-8105</issn><eissn>1820-7383</eissn><abstract>Treatment-resistant mood and anxiety disorders require an intensive therapeutic approach, and it should balance benefits and adverse effects or other potential detrimental effects of medications. The goal of treatment is to provide consistent and lasting improvement in symptoms of depression and anxiety. Beozodiazepines are effective for anxiety symptoms, but with no sustained treatment effects. Other medication treatment options for anxiety disorders are outlined. Ketamine is usually very effective in treating maior depressive disorder but without sustained benefits. Loog-term use may pose a signiticant risk of developing tolerance and dependence. Stimulant medication augmentation for treatment-resistant depression is effective for residual symptoms of depression, but effects are usually short-lasting and it sounds mor as an artificial way of improving energy, alertness and cognitive functioning. Synthetic cannabinoids and medical marijuana are increasingly prescribed for various medical conditions. but more recently also for patients with mood and anxiety disorders. All of these treatments may raise ethical dilemmas about appropriateness of prescribing these medications and a number of questions regarding the optimal treatment for patients with treatment-resistant depression and treatment refractory anxiety disorders.</abstract><cop>Serbia</cop><pmid>29693845</pmid><doi>10.2298/mpns1606171k</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-8105
ispartof Medicinski pregled, 2016-10, Vol.69 (5-6), p.171-176
issn 0025-8105
1820-7383
language eng
recordid cdi_proquest_miscellaneous_2030936061
source EZB-FREE-00999 freely available EZB journals
title CRITICAL REVIEW OF AVAILABLE TREATMENT OPTIONS FOR TREATMENT REFRACTORY DEPRESSION AND ANXIETY - CLINICAL AND ETHICAL DILEMMAS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T05%3A36%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CRITICAL%20REVIEW%20OF%20AVAILABLE%20TREATMENT%20OPTIONS%20FOR%20TREATMENT%20REFRACTORY%20DEPRESSION%20AND%20ANXIETY%20-%20CLINICAL%20AND%20ETHICAL%20DILEMMAS&rft.jtitle=Medicinski%20pregled&rft.au=Kolar,%20Dusan&rft.date=2016-10-01&rft.volume=69&rft.issue=5-6&rft.spage=171&rft.epage=176&rft.pages=171-176&rft.issn=0025-8105&rft.eissn=1820-7383&rft_id=info:doi/10.2298/mpns1606171k&rft_dat=%3Cproquest_cross%3E2030936061%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2030936061&rft_id=info:pmid/29693845&rfr_iscdi=true